Effects of nomifensine and desipramine on the sequelae of intracerebrally-injected 6-OHDA and 5,6-DHT.
Pretreatment with either nomifensine or desipramine (15 mg/kg) attenuated the depletion of forebrain noradrenaline induced by unilateral 6-hydroxydopamine lesions of the medial forebrain bundle. Neither pretreatment influenced the depletions of striatal dopamine induced by medial forebrain bundle lesions with 6-hydroxydopamine or 5,6-dihydroxytryptamine, or contralateral rotational responses to apomorphine in the 6-hydroxydopamine-lesioned animals. Pretreatment with nomifensine attenuated the depletion of striatal dopamine induced by intrastriatal injections of 6-hydroxydopamine, consistent with inhibition of dopamine uptake in vivo. Nomifensine may differently influence distinct axonal and terminal uptake mechanisms for dopamine.
D015115:5,6-Dihydroxytryptamine / Q000494:pharmacology*; D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D001923:Brain Chemistry / Q000187:drug effects; D003891:Desipramine / Q000494:pharmacology*; D004298:Dopamine / Q000378:metabolism; D006801:Humans; D006892:Hydroxydopamines / Q000494:pharmacology*; D007546:Isoquinolines / Q000494:pharmacology*; D008297:Male; D009627:Nomifensine / Q000494:pharmacology*; D051381:Rats; D012701:Serotonin / Q000378:metabolism; D013239:Stereotyped Behavior / Q000187:drug effects
D006892:Hydroxydopamines; D007546:Isoquinolines; D009627:Nomifensine; D012701:Serotonin; D001058:Apomorphine; D003891:Desipramine; D004298:Dopamine; D015115:5,6-Dihydroxytryptamine